Obinutuzumab

{
  "id": "MLC-T-ONC-005994",
  "term": "Obinutuzumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with other drugs to treat certain types of follicular lymphoma and chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. Obinutuzumab binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Gazyva.",
    "A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells."
  ],
  "synonyms": [
    "Gazyva",
    "afutuzumab",
    "anti-CD20 monoclonal antibody R7159",
    "huMAB(CD20)"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/obinutuzumab/"
}